KR100748299B1 - 아졸 화합물의 수용성 프로드럭 - Google Patents

아졸 화합물의 수용성 프로드럭 Download PDF

Info

Publication number
KR100748299B1
KR100748299B1 KR1020027009320A KR20027009320A KR100748299B1 KR 100748299 B1 KR100748299 B1 KR 100748299B1 KR 1020027009320 A KR1020027009320 A KR 1020027009320A KR 20027009320 A KR20027009320 A KR 20027009320A KR 100748299 B1 KR100748299 B1 KR 100748299B1
Authority
KR
South Korea
Prior art keywords
formula
compound
hydrogen
pharmaceutically acceptable
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027009320A
Other languages
English (en)
Korean (ko)
Other versions
KR20020070492A (ko
Inventor
야스쯔꾸 우에다
존 디. 마티스켈라
저지 고릭
토마스 더블유. 휴다이마
충-핀 첸
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20020070492A publication Critical patent/KR20020070492A/ko
Application granted granted Critical
Publication of KR100748299B1 publication Critical patent/KR100748299B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymerization Catalysts (AREA)
KR1020027009320A 2000-01-20 2001-01-16 아졸 화합물의 수용성 프로드럭 Expired - Lifetime KR100748299B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17716900P 2000-01-20 2000-01-20
US60/177,169 2000-01-20
US24996900P 2000-11-20 2000-11-20
US60/249,969 2000-11-20

Publications (2)

Publication Number Publication Date
KR20020070492A KR20020070492A (ko) 2002-09-09
KR100748299B1 true KR100748299B1 (ko) 2007-08-09

Family

ID=26873001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027009320A Expired - Lifetime KR100748299B1 (ko) 2000-01-20 2001-01-16 아졸 화합물의 수용성 프로드럭

Country Status (22)

Country Link
US (1) US6362172B2 (enExample)
EP (1) EP1284737B1 (enExample)
JP (1) JP3766804B2 (enExample)
KR (1) KR100748299B1 (enExample)
CN (1) CN1178665C (enExample)
AT (1) ATE300946T1 (enExample)
AU (1) AU782177C (enExample)
BR (1) BR0107618A (enExample)
CA (1) CA2397734C (enExample)
CZ (1) CZ20022822A3 (enExample)
DE (1) DE60112433T2 (enExample)
DK (1) DK1284737T5 (enExample)
ES (1) ES2247131T3 (enExample)
HU (1) HU229226B1 (enExample)
IL (2) IL150798A0 (enExample)
MX (1) MXPA02007120A (enExample)
NO (1) NO330352B1 (enExample)
NZ (1) NZ519354A (enExample)
PL (1) PL206024B1 (enExample)
PT (1) PT1284737E (enExample)
RU (1) RU2266909C2 (enExample)
WO (1) WO2001052852A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1964843B1 (en) * 2005-12-20 2013-08-28 Eisai R&D Management Co., Ltd. Process for production of water-soluble azole prodrug
WO2007092580A2 (en) * 2006-02-08 2007-08-16 Phibro-Tech Inc. Biocidal azole emulsion concentrates having high active ingredient content
KR101250632B1 (ko) 2006-02-22 2013-04-03 에자이 알앤드디 매니지먼트 가부시키가이샤 안정화 의약 조성물
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
JP5757864B2 (ja) * 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
AU2009249069A1 (en) * 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
WO2012060448A1 (ja) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103402543B (zh) * 2010-12-16 2015-09-16 德克萨斯州立大学董事会 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
IN2014DN06792A (enExample) * 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9981040B2 (en) * 2012-04-20 2018-05-29 Eisai R&D Management Co., Ltd. Capsule formulation
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014195872A1 (en) 2013-06-04 2014-12-11 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
CN113559105B (zh) 2014-01-29 2026-06-23 维奥姆治疗有限公司 抗性痤疮的治疗
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN104926870B (zh) * 2014-03-21 2017-02-08 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法
EP3328819B1 (en) * 2015-07-28 2020-04-01 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compounds prodrugs and their uses
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN107501255B (zh) * 2017-09-12 2019-08-23 成都施贝康生物医药科技有限公司 一种艾沙康唑衍生物及其用途
CN108676031A (zh) * 2018-05-29 2018-10-19 重庆威鹏药业有限公司 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639577A1 (en) * 1993-08-17 1995-02-22 Bristol-Myers Squibb Company Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents
EP0747385A1 (en) * 1995-06-06 1996-12-11 Bristol-Myers Squibb Company Prodrugs of paclitaxel derivatives
WO1997028169A1 (en) * 1996-02-02 1997-08-07 Pfizer Research And Development Company, N.V./S.A. Triazole derivatives useful in therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
NO310238B1 (no) 1992-12-24 2001-06-11 Bristol Myers Squibb Co Kjemiske forbindelser og farmasöytisk preparat samt anvendelse av slike preparater
DK0736030T3 (da) 1993-12-21 2001-10-29 Schering Corp Fungicide tetrahydrofuraner
US5714490A (en) * 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
SG48386A1 (en) 1994-01-24 1998-04-17 Janssen Pharmaceutica Nv Watersoluble azole antifungals
NZ270418A (en) 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
EP0829478A3 (en) 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
DK1056754T3 (da) 1998-01-29 2004-02-16 Bristol Myers Squibb Co Phosphatderivater af diaryl-1,3,4-oxadiazolon
US5883097A (en) 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
WO2000030655A1 (en) * 1998-11-20 2000-06-02 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639577A1 (en) * 1993-08-17 1995-02-22 Bristol-Myers Squibb Company Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents
EP0747385A1 (en) * 1995-06-06 1996-12-11 Bristol-Myers Squibb Company Prodrugs of paclitaxel derivatives
WO1997028169A1 (en) * 1996-02-02 1997-08-07 Pfizer Research And Development Company, N.V./S.A. Triazole derivatives useful in therapy

Also Published As

Publication number Publication date
PL206024B1 (pl) 2010-06-30
AU782177B2 (en) 2005-07-07
EP1284737A4 (en) 2003-03-19
NO20023468D0 (no) 2002-07-19
CA2397734A1 (en) 2001-07-26
AU2948501A (en) 2001-07-31
ES2247131T3 (es) 2006-03-01
CA2397734C (en) 2010-08-17
AU782177C (en) 2007-10-18
RU2266909C2 (ru) 2005-12-27
HUP0204405A2 (en) 2003-05-28
CZ20022822A3 (cs) 2003-02-12
CN1395485A (zh) 2003-02-05
PT1284737E (pt) 2005-11-30
NZ519354A (en) 2004-05-28
EP1284737B1 (en) 2005-08-03
US6362172B2 (en) 2002-03-26
EP1284737A1 (en) 2003-02-26
IL150798A (en) 2006-08-01
HU229226B1 (en) 2013-09-30
KR20020070492A (ko) 2002-09-09
PL356164A1 (en) 2004-06-14
CN1178665C (zh) 2004-12-08
DK1284737T3 (da) 2005-11-28
JP3766804B2 (ja) 2006-04-19
WO2001052852A1 (en) 2001-07-26
DE60112433D1 (de) 2005-09-08
DK1284737T5 (da) 2007-09-24
ATE300946T1 (de) 2005-08-15
DE60112433T2 (de) 2006-05-18
JP2003520235A (ja) 2003-07-02
US20010041691A1 (en) 2001-11-15
NO20023468L (no) 2002-07-29
BR0107618A (pt) 2002-11-12
IL150798A0 (en) 2003-02-12
HUP0204405A3 (en) 2005-02-28
NO330352B1 (no) 2011-04-04
MXPA02007120A (es) 2003-01-28

Similar Documents

Publication Publication Date Title
KR20020070492A (ko) 아졸 화합물의 수용성 프로드럭
KR100734456B1 (ko) 수용성 아졸 화합물의 개선된 제조 방법
AU2002213317A1 (en) Improved process for water soluble azole compounds
IL187059A (en) Monolysin salts of azole compounds, their preparation and medicinal preparations containing them
US6620934B2 (en) Water soluble prodrugs of azole compounds
ZA200204332B (en) Water soluble prodrugs of azole compounds.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020719

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060103

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20060306

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20061115

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20070227

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070409

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20070710

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070803

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070803

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20080417

FPAY Annual fee payment

Payment date: 20100728

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20100728

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20110727

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20110727

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20120727

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130726

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130726

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140725

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140725

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150724

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150724

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160722

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160722

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20170721

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20170721

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20180727

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20180727

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20190726

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20190726

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20200724

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20200724

Start annual number: 14

End annual number: 14

EXPY Expiration of term
PC1801 Expiration of term